However, Gao et al. found that HCC cells with low c-Met levels exhibited primary resistance to c-MET inhibitors, and the combination of cabozantinib and the mTOR inhibitor rapamycin exerted synergistic inhibitory effects on cell proliferation and tumor growth in resistant cells (Gao et al., 2021; Shang et al., 2021). The gene discussed is MET; the disease is hepatocellular carcinoma.